CGI entered into a collaborative research agreement and non-exclusive license arrangement with Cleveland Clinic to start development around a renal cell carcinoma diagnostic focused on validating genomic biomarkers from DNA. CGI received numerous clinical specimens from the Cleveland Clinic and associated clinical and laboratory data was used for the validation of CGI’s proprietary microarray, UroGenRA™–Kidney. Samples were analyzed in CGI’s clinical laboratory and resulting data will be published jointly.